Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 Prime-Boost Vaccine Regimens
NCT02251288Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2015
- Primary completion
- Aug 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of H7N9 Anhui 2013/AA ca in Avian Influenza (AI) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric mean titers determined by neuraminidase inhibiting antibody by enzyme-linked lectin assay (ELLA) at Day 197, Occurrence of respiratory reactogenicity following pLAIV vaccination and 6 more. Started May 2015; status: completed.
02
Drugs
H7N9 Anhui 2013/AA ca
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT02251288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251288.